GAS5: GAS5 is a long noncoding RNA (lncRNA) that is involved in various biological processes, including cell growth, proliferation, and survival [PMC4661729]. It has been shown to be elevated in response to Acinetobacter baumannii infection [PMC8312602]. In the context of Parkinson's disease (PD), GAS5 has been found to promote the microglial inflammatory response by competitively binding to miR-223-3p and activating the NLRP3 pathway [PMC8603508]. Low expression levels of GAS5 have been associated with the progression of chronic heart failure by regulating miR-223-3p [PMC9175270]. GAS5 has also been shown to regulate the NLRP3 pathway by sponging miR223‐3p in PD, leading to microglial inflammation [PMC9477794]. In experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), GAS5 is significantly increased in microglia and its modification affects the severity of EAE [PMC5623836]. Additionally, GAS5 has been found to suppress microglial M2 polarization and promote M1 polarization following oxygen-glucose deprivation/reoxygenation (OGD/R) injury [PMC6704123]. In gliomas, GAS5 expression levels are reduced compared to normal brain tissues and are associated with longer survival time [PMC6377997][PMC7400976][PMC9465381][PMC7738835][PMC9164261][PMID6377997][PMID7400976][PMID9465381][PMID7738835]. Overall, GAS5 is a versatile lncRNA that plays a role in various diseases and biological processes. It can regulate inflammation, cell polarization, proliferation, and survival. Its dysregulation has been implicated in diseases such as Parkinson's disease, chronic heart failure, multiple sclerosis, and gliomas. Further research is needed to fully understand the mechanisms and potential therapeutic applications of GAS5.